Antares declares a Phase III win for 'low-T' shot; Shkreli returns with another biotech startup;

@FierceBiotech: Little Neos gets a $20M bankroll to prep ADHD drugs for FDA review. News | Follow @FierceBiotech

@JohnCFierce: Top 10 drug brands by payments to doctors, from the FiercePharma Marketing team. Special report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online. Listen | Follow @DamianFierce

> Antares Pharma ($ATRS) said its weekly testosterone injection met its primary endpoint in a Phase III study. The treatment is facing an indeterminate delay in its regulatory future after the FDA asked for more safety data last month. More

> Months removed from an unceremonious firing from the last company he started, hedge fund veteran Martin Shkreli has launched Turing Pharmaceuticals, a new biotech focused on acquiring drugs that can be repurposed for lucrative indications. News

> Isis Pharmaceuticals ($ISIS) is touting positive Phase I results for a new treatment for hereditary angioedema. Item

Medical Device News

@FierceMedDev: Reuters: Boston Scientific close to $2B deal for Endo's AMS device unit. Report | Follow @FierceMedDev

@VarunSaxena2: From my med tech M&A special report: Zimmer swallowing up Biomet, leading to chain of other deals. More | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics here, feat. 23andMe, $RHHBY and a new collaboration for Alzheimer's Dx. Newsletter | Follow @EmilyWFierce

> FDA in midst of updating endoscope labels implicated in 'superbug' infections. Report

> FDA weighs in on Intuitive Surgical recall of da Vinci vessel sealer due to inadequate grasping. More

Pharma News

@FiercePharma: ICYMI yesterday: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: In case you missed our newest special: Top 10 drug brands by payments to doctors. Report | Follow @CarlyHFierce

> J&J loses first court battle over Risperdal's breast-growth side effects. Story

> California lawmaker calling for more pricing transparency for costly meds. News

> Takeda will grow again in the coming year, COO Weber promises. Article

Drug Delivery News

> OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates. Report

> MIT team injects drug-carrying hydrogel that 're-heals' in the body. Story

> WHO adopts new safety needle policy, calling smart syringes an 'urgent priority.' Article

> Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel. Item

> FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug. News

Diagnostics News

> Israeli colon capsule maker reels in $24M in IPO and private placement. More

> Roche, BioMed X to jointly run diagnostics incubator in Germany. Article

> Foundation Medicine rides tailwinds of successful Q4 2014. Item

> Department of Defense gives contractor $14.8M to test so-called Sample-to-Sequence system. Report

> 23andMe scores FDA OK to market genetic carrier test direct to consumers. News

Pharma Marketing News

> Can Pfizer's new breast cancer med really cruise to $4B and beyond? Article

> Shire's Vyvanse brand team draws fire for aggressive binge-eating push. More

> British doctors lobby NHS to use cheap Avastin over Lucentis in AMD. Report

> With peglispro shunted aside, Lilly could go full-tilt after Lantus. Story

> Valeant to keep specialty Salix reps, but it's eyeing primary care for potential cuts. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.